The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation

被引:41
作者
Ho, GT
Seddon, AJ
Therapondos, G
Satsangi, J
Hayes, PC
机构
[1] Lothian Univ Hosp, New Royal Infirm, NHS Trust, Scottish Liver Transplant Unit, Edinburgh EH16 4SA, Midlothian, Scotland
[2] Western Gen Hosp, Gastrointestinal Unit, Edinburgh EH4 2XU, Midlothian, Scotland
关键词
course; immunosuppression; OLT; PSC; UC;
D O I
10.1097/00042737-200512000-00018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims The course of ulcerative colitis (UC) following orthotopic liver transplantation (OLT) for primary sclerosing cholangitis (PSC) is unclear. We documented the nationwide experience of the course of UC, before and after OLT for PSC. Methods and results A total of 470 liver transplants were performed for 413 patients between 1992 and 2003, in the Scottish Liver Transplantation Unit, UK. Twenty-six patients had co-existing UC/PSC. Of these, data fro m 20 patients were studied over a median period of 11.9 years before OLT and 4.4 years after OLT; of the others, four patients required colectomy prior to OLT, one died within 7 days of transplant, and one developed UC after transplant. A significantly higher relapse rate (number of relapses/year of follow-up) was seen after OLT (median 1.0 versus 0.3; interquartile range, 0.10-1.42 and 0.01-0.40, respectively; P=0.007). The corticosteroids requirement (number of courses/year of follow-up) after OLT was also significantly higher (0.40 versus 0.10; interquartile range, 0.51-1.13 and 0.05-0.12, respectively; P=0.003). Twenty per cent of patients (4/20) became corticosteroid dependent after OLT. Thirty-five per cent of patients (7/20) underwent colectomy after OLT: three for severe disease and four for neoplasia/ dysplasia. Five patients (19%) developed neoplasia following OLT. Conclusion Despite immunosuppression, UC follows a more aggressive clinical course after OLT and is associated with a high rate of neoplasia. Eur J Gastroenterol Hepatol 17:1379-1385 (c) 2005 Lippincott Williams & Wilkins.
引用
收藏
页码:1379 / 1385
页数:7
相关论文
共 34 条
[1]
Clinical course and management of inflammatory bowel disease after liver transplantation [J].
Befeler, AS ;
Lissoos, TW ;
Schiano, TD ;
Conjeevaram, H ;
Dasgupta, KA ;
Millis, JM ;
Newell, KA ;
Thistlethwaite, JR ;
Baker, AL .
TRANSPLANTATION, 1998, 65 (03) :393-396
[2]
INCREASED RISK OF EARLY COLORECTAL NEOPLASMS AFTER HEPATIC TRANSPLANT IN PATIENTS WITH INFLAMMATORY BOWEL-DISEASE [J].
BLEDAY, R ;
LEE, E ;
JESSURUN, J ;
HEINE, J ;
WONG, WD .
DISEASES OF THE COLON & RECTUM, 1993, 36 (10) :908-912
[3]
Risk and natural history of colonic neoplasia in patients with primacy sclerosing cholangitis and ulcerative colitis [J].
Brentnall, TA ;
Haggitt, RC ;
Rabinovitch, PS ;
Kimmey, MB ;
Bronner, MP ;
Levine, DS ;
Kowdley, KV ;
Stevens, AC ;
Crispin, DA ;
Emond, M ;
Rubin, CE .
GASTROENTEROLOGY, 1996, 110 (02) :331-338
[4]
BROOME U, 1995, HEPATOLOGY, V22, P1404, DOI 10.1002/hep.1840220511
[5]
The management of primary sclerosing cholangitis [J].
Roger W. Chapman .
Current Gastroenterology Reports, 2003, 5 (1) :9-17
[6]
The colon and PSC: new liver, new danger? [J].
Chapman, RW .
GUT, 1998, 43 (05) :595-596
[7]
DHAENS GR, 1993, AM J GASTROENTEROL, V88, P1174
[8]
EPIDEMIOLOGY OF PRIMARY SCLEROSING CHOLANGITIS IN SPAIN [J].
ESCORSELL, A ;
PARES, A ;
RODES, J ;
SOLISHERRUZO, JA ;
MIRAS, M ;
DELAMORENA, E .
JOURNAL OF HEPATOLOGY, 1994, 21 (05) :787-791
[9]
GAVALER JS, 1991, DIG DIS, P321
[10]
Orthotopic liver transplantation for primary sclerosing cholangitis - A 12-year single center experience [J].
Goss, JA ;
Shackleton, CR ;
Farmer, DG ;
Arnaout, WS ;
Seu, P ;
Markowitz, JS ;
Martin, P ;
Stribling, RJ ;
Goldstein, LI ;
Busuttil, RW .
ANNALS OF SURGERY, 1997, 225 (05) :472-481